JP2025165976A5 - - Google Patents

Info

Publication number
JP2025165976A5
JP2025165976A5 JP2025120874A JP2025120874A JP2025165976A5 JP 2025165976 A5 JP2025165976 A5 JP 2025165976A5 JP 2025120874 A JP2025120874 A JP 2025120874A JP 2025120874 A JP2025120874 A JP 2025120874A JP 2025165976 A5 JP2025165976 A5 JP 2025165976A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
oligonucleotide according
chiral
independently
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025120874A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025165976A (ja
Filing date
Publication date
Priority claimed from PCT/US2020/054436 external-priority patent/WO2021071858A1/en
Application filed filed Critical
Publication of JP2025165976A publication Critical patent/JP2025165976A/ja
Publication of JP2025165976A5 publication Critical patent/JP2025165976A5/ja
Pending legal-status Critical Current

Links

JP2025120874A 2019-10-06 2025-07-17 オリゴヌクレオチド組成物及びその使用方法 Pending JP2025165976A (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201962911334P 2019-10-06 2019-10-06
US62/911,334 2019-10-06
US202062959917P 2020-01-11 2020-01-11
US62/959,917 2020-01-11
US202063022559P 2020-05-10 2020-05-10
US63/022,559 2020-05-10
US202063069696P 2020-08-24 2020-08-24
US63/069,696 2020-08-24
PCT/US2020/054436 WO2021071858A1 (en) 2019-10-06 2020-10-06 Oligonucleotide compositions and methods of use thereof
JP2022520901A JP7766589B2 (ja) 2019-10-06 2020-10-06 オリゴヌクレオチド組成物及びその使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022520901A Division JP7766589B2 (ja) 2019-10-06 2020-10-06 オリゴヌクレオチド組成物及びその使用方法

Publications (2)

Publication Number Publication Date
JP2025165976A JP2025165976A (ja) 2025-11-05
JP2025165976A5 true JP2025165976A5 (https=) 2026-03-19

Family

ID=75437497

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022520901A Active JP7766589B2 (ja) 2019-10-06 2020-10-06 オリゴヌクレオチド組成物及びその使用方法
JP2025120874A Pending JP2025165976A (ja) 2019-10-06 2025-07-17 オリゴヌクレオチド組成物及びその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022520901A Active JP7766589B2 (ja) 2019-10-06 2020-10-06 オリゴヌクレオチド組成物及びその使用方法

Country Status (11)

Country Link
US (1) US20230220384A1 (https=)
EP (1) EP4022059A4 (https=)
JP (2) JP7766589B2 (https=)
KR (1) KR20220076508A (https=)
CN (1) CN114585737A (https=)
AU (1) AU2020363391A1 (https=)
BR (1) BR112022006205A2 (https=)
CA (1) CA3154768A1 (https=)
IL (1) IL291933A (https=)
MX (1) MX2022004101A (https=)
WO (1) WO2021071858A1 (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
JP6453212B2 (ja) 2012-07-13 2019-01-16 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． キラル制御
ES2917473T3 (es) 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
CN108135921B (zh) 2015-07-22 2023-10-17 波涛生命科学有限公司 寡核苷酸组合物及其方法
CA3015823A1 (en) 2016-03-13 2017-09-21 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
CN109562122A (zh) 2016-06-03 2019-04-02 波涛生命科学有限公司 寡核苷酸、组合物及其方法
EP3475424A1 (en) 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
US10941402B2 (en) 2016-09-01 2021-03-09 Proqr Therapeutics Ii B.V. Chemically modified single-stranded RNA-editing oligonucleotides
MA46905A (fr) 2016-11-23 2019-10-02 Wave Life Sciences Ltd Compositions et procédés de synthèse de phosphoramidites et d'oligonucléotides
US11603532B2 (en) 2017-06-02 2023-03-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US11597927B2 (en) 2017-06-02 2023-03-07 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US11718638B2 (en) 2017-06-21 2023-08-08 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
TW201920672A (zh) 2017-08-08 2019-06-01 新加坡商波濤生命科學有限公司 寡核苷酸組合物及其使用方法
CN111108096A (zh) 2017-09-18 2020-05-05 波涛生命科学有限公司 寡核苷酸制备技术
EP3694530A4 (en) 2017-10-12 2021-06-30 Wave Life Sciences Ltd. COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
IL277889B2 (en) 2018-04-12 2025-01-01 Wave Life Sciences Ltd Oligonucleotide preparations and methods of using them
EP3790596A4 (en) 2018-05-11 2022-04-06 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
CN113748116A (zh) * 2019-03-20 2021-12-03 波涛生命科学有限公司 可用于寡核苷酸制备的技术
WO2022046667A1 (en) * 2020-08-24 2022-03-03 Wave Life Sciences Ltd. Cells and non-human animals engineered to express adar1 and uses thereof
EP4240849A4 (en) * 2020-11-08 2026-04-01 Wave Life Sciences Ltd OLIGONUCLEOTIDE COMPOSITIONS AND ASSOCIATED PROCESSES
US20230194709A9 (en) * 2021-06-29 2023-06-22 Seagate Technology Llc Range information detection using coherent pulse sets with selected waveform characteristics
WO2023278410A1 (en) * 2021-06-29 2023-01-05 Korro Bio, Inc. Methods and compositions for adar-mediated editing
AU2022352779A1 (en) * 2021-09-26 2024-03-28 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
US20250154504A1 (en) 2022-02-14 2025-05-15 Proqr Therapeutics Ii B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
CN119452084A (zh) * 2022-05-12 2025-02-14 波涛生命科学有限公司 寡核苷酸组合物及其方法
WO2023220428A1 (en) * 2022-05-12 2023-11-16 Wave Life Sciences Ltd. Compositions for editing ass1 transcripts and methods thereof
WO2024013360A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Chemically modified oligonucleotides for adar-mediated rna editing
EP4555086A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Oligonucleotides for adar-mediated rna editing and use thereof
JP2025525564A (ja) * 2022-07-18 2025-08-05 エフ． ホフマン－ラ ロシュ アーゲー オリゴヌクレオチドの編集
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
AR131145A1 (es) 2022-11-24 2025-02-19 Proqr Therapeutics Ii Bv Oligonucleótidos antisentido para el tratamiento de hemocromatosis hfe hereditaria
WO2024114908A1 (en) 2022-11-30 2024-06-06 Eberhard Karls Universität Tübingen Chemically modified antisense oligonucleotides (asos) and compositions comprising the same for rna editing
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
CA3276262A1 (en) 2022-12-09 2024-06-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
EP4669753A1 (en) 2023-02-20 2025-12-31 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
WO2024175586A2 (en) 2023-02-21 2024-08-29 Vib Vzw Inhibitors of synaptogyrin-3 expression
JP2026507051A (ja) 2023-02-21 2026-02-27 ブイアイビー ブイゼットダブリュ シナプトギリン－３発現を調節するためのオリゴヌクレオチド
EP4432289A1 (en) 2023-03-15 2024-09-18 Shape Therapeutics Inc. Generative sequence screening with conditional gans, diffusion models, and denoising diffusion conditional gans
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
WO2024206175A1 (en) 2023-03-24 2024-10-03 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
AU2024246572A1 (en) 2023-03-27 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease
WO2024256620A1 (en) 2023-06-16 2024-12-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurodegenerative disease
AU2024287308A1 (en) 2023-07-13 2025-12-18 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
AU2024325709A1 (en) 2023-08-15 2026-01-29 Airna Corporation Chemically modified antisense oligonucleotides (asos) and compositions for rna editing
WO2025051946A1 (en) 2023-09-07 2025-03-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
AU2024354150A1 (en) * 2023-09-28 2026-03-12 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
WO2025073902A1 (en) 2023-10-06 2025-04-10 Eberhard Karls Universität Tübingen Chemical and sequence optimisation of antisense oligonucleotides for adar-mediated rna editing
WO2025083268A1 (en) 2023-10-20 2025-04-24 Airna Corporation Chemically modified antisense oligonucleotides (asos) and compositions comprising the same for rna editing
CN121909203A (zh) 2023-10-31 2026-04-21 科罗生物公司 包含氨基磷酸酯核苷酸间键的寡核苷酸
WO2025104239A1 (en) 2023-11-16 2025-05-22 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
WO2025128799A1 (en) 2023-12-12 2025-06-19 Korro Bio, Inc. Double-stranded rna-editing oligonucleotides and uses thereof
WO2025132708A1 (en) 2023-12-20 2025-06-26 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease
WO2025172372A1 (en) 2024-02-12 2025-08-21 Airna Corporation Conjugate for targeted delivery of an antisense oligonucleotide
GB202404661D0 (en) 2024-04-02 2024-05-15 Proqr Therapeutics Ii Bv Antisense oligoncleotides for the treatment of liver disease
WO2025224230A1 (en) 2024-04-25 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of fatty liver disease
GB202410081D0 (en) 2024-07-11 2024-08-28 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of cardiovascular disease
WO2026022136A1 (en) 2024-07-23 2026-01-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2026050243A1 (en) 2024-08-26 2026-03-05 Korro Bio, Inc. Galnac conjugated oligonucleotides for rna editing
WO2026060374A2 (en) 2024-09-16 2026-03-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
WO2026068781A1 (en) 2024-09-30 2026-04-02 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014169206A2 (en) * 2013-04-11 2014-10-16 Carnegie Mellon University Divalent nucleobase compounds and uses therefor
ES2917473T3 (es) * 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
RU2708237C2 (ru) * 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
US10787664B2 (en) * 2015-05-26 2020-09-29 City Of Hope Compounds of chemically modified oligonucleotides and methods of use thereof
JP7511326B2 (ja) * 2015-10-09 2024-07-05 ウェイブ ライフ サイエンシズ リミテッド オリゴヌクレオチド組成物およびその方法
CN109562122A (zh) * 2016-06-03 2019-04-02 波涛生命科学有限公司 寡核苷酸、组合物及其方法
US10941402B2 (en) * 2016-09-01 2021-03-09 Proqr Therapeutics Ii B.V. Chemically modified single-stranded RNA-editing oligonucleotides
US11718638B2 (en) * 2017-06-21 2023-08-08 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis

Similar Documents

Publication Publication Date Title
JP2025165976A5 (https=)
AU2022202011B2 (en) Short interfering nucleic acid (siNA) molecules containing a 2' internucleoside linkage
JP7740719B2 (ja) ホスホルアミダイト化学を使用する骨格修飾モルホリノオリゴヌクレオチド及びキメラの合成
ES2924806T3 (es) Análogos de 4'-fosfato y oligonucleótidos que comprenden el mismo
KR100875003B1 (ko) 누클레오시드의 위치 변형에 의한 올리고누클레오티드 ＣｐＧ 매개성 면역 자극의 조절
JP3831407B2 (ja) メチルホスホン酸エステル、その製造方法およびその使用
US7176296B2 (en) Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
JP5520818B2 (ja) Ｒｎａ合成のためのチオ炭素保護基
US7105495B2 (en) Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
JPWO2021030778A5 (https=)
JPWO2021071858A5 (https=)
JP2003520811A (ja) ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ誘導性免疫刺激の調節
EP3728591B1 (en) Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
WO2019182037A1 (ja) 毒性が低減されたアンチセンスオリゴヌクレオチド
JPWO2019022196A1 (ja) 一本鎖オリゴヌクレオチド
JP7624221B2 (ja) 一本鎖ポリヌクレオチド
EP0749436A1 (en) Compositions and methods for use in the synthesis of oligonucleotides
JPWO2020041769A5 (https=)
DE69725440T2 (de) 2-substituierte nukleosid- und oligonukleotid- derivate
JP4791665B2 (ja) 接合体ならびにそれらの製造方法および生体膜を横切り分子を輸送するためのそれらの使用
WO1994004550A1 (en) Cholesteryl-modified triple-helix forming oligonucleotides and uses thereof
JP2000509724A (ja) ヌクレオチド又はオリゴヌクレオチドホスホロアミダイトの合成方法
JPWO2021187392A5 (https=)
JPWO2023049475A5 (https=)
EP3728592B1 (en) Oligonucleotides comprising a phosphorodithioate internucleoside linkage